Total Asset Turnover
since 2012
Paying user area
Try for free
Zoetis Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Zoetis Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Zoetis Inc., total asset turnover, long-term trends, calculation
| Total asset turnover | = | Revenue1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|
| Dec 31, 2023 | = | ÷ | |||
| Dec 31, 2022 | = | ÷ | |||
| Dec 31, 2021 | = | ÷ | |||
| Dec 31, 2020 | = | ÷ | |||
| Dec 31, 2019 | = | ÷ | |||
| Dec 31, 2018 | = | ÷ | |||
| Dec 31, 2017 | = | ÷ | |||
| Dec 31, 2016 | = | ÷ | |||
| Dec 31, 2015 | = | ÷ | |||
| Dec 31, 2014 | = | ÷ | |||
| Dec 31, 2013 | = | ÷ | |||
| Dec 31, 2012 | = | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$ in millions
- Revenue Trends
- Revenue demonstrated a consistent upward trend over the period, increasing from $4,336 million in 2012 to $8,544 million in 2023. This represents nearly a doubling of revenue within eleven years, with a particularly notable acceleration after 2019, where revenue rose from $6,675 million to $8,544 million by 2023. The growth appears steady with only a slight plateau during 2014-2015 where revenue slightly decreased from $4,785 million to $4,765 million, but thereafter, it resumed an upward trajectory.
- Total Assets Analysis
- Total assets increased from $6,262 million in 2012 to $14,286 million in 2023, showing substantial growth and expansion of asset base. There was a significant jump between 2017 and 2018, where total assets rose from $8,586 million to $10,777 million. The growth trend continued, peaking just below $15 billion in 2022 before slightly declining in 2023. This indicates ongoing investment and expansion, possibly reflecting acquisitions, capital expenditure, or increased asset holdings linked to business growth.
- Total Asset Turnover Ratio Insights
- The total asset turnover ratio declined overall from 0.69 in 2012 to 0.60 in 2023, indicating that revenue generated per dollar of assets decreased during the period. Initially, the ratio hovered between 0.69 and 0.72 until 2014, followed by a decline with some fluctuations. The lowest values were observed around 2018-2020, with ratios near 0.49 to 0.54, suggesting less efficient asset utilization during these years. A moderate recovery is seen towards 2023, but it remains below early period levels. This trend may reflect the company's asset base increasing at a faster rate than revenue, possibly due to investments that have not yet fully translated into proportional revenue growth.
- Summary
- The overall financial pattern indicates strong revenue growth accompanied by significant increases in total assets. However, the declining total asset turnover ratio suggests that asset efficiency has diminished somewhat, as revenue growth has not kept pace proportionally with increases in asset base. The recent partial recovery in asset turnover might indicate improved utilization or the maturation of prior investments. Continued monitoring of this ratio alongside revenue growth will be important to assess the effectiveness of asset deployment in future periods.
Comparison to Competitors
Zoetis Inc., total asset turnover, long-term trends, comparison to competitors
| Zoetis Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2023 | |||||||||||||
| Dec 31, 2022 | |||||||||||||
| Dec 31, 2021 | |||||||||||||
| Dec 31, 2020 | |||||||||||||
| Dec 31, 2019 | |||||||||||||
| Dec 31, 2018 | |||||||||||||
| Dec 31, 2017 | |||||||||||||
| Dec 31, 2016 | |||||||||||||
| Dec 31, 2015 | |||||||||||||
| Dec 31, 2014 | |||||||||||||
| Dec 31, 2013 | |||||||||||||
| Dec 31, 2012 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Zoetis Inc., total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Zoetis Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 | ||
| Dec 31, 2017 | ||
| Dec 31, 2016 | ||
| Dec 31, 2015 | ||
| Dec 31, 2014 | ||
| Dec 31, 2013 | ||
| Dec 31, 2012 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
Zoetis Inc., total asset turnover, long-term trends, comparison to industry (health care)
| Zoetis Inc. | Health Care | |
|---|---|---|
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 31, 2019 | ||
| Dec 31, 2018 | ||
| Dec 31, 2017 | ||
| Dec 31, 2016 | ||
| Dec 31, 2015 | ||
| Dec 31, 2014 | ||
| Dec 31, 2013 | ||
| Dec 31, 2012 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).